Vimarsana
Biggest News Aggregation in the World

Mol Ther News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mol Ther. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mol Ther Today - Breaking & Trending Today

The Nobel Prize in Physiology or Medicine 2023 - Vimarsana News

The Nobel Prize in Physiology or Medicine 2023

The Nobel Prize in Physiology or Medicine 2023 was awarded jointly to Katalin Karikó and Drew Weissman "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19"

Katalin Kariko and Drew Weissman win 2023 Nobel Prize in Medicine - Vimarsana News

Katalin Kariko and Drew Weissman win 2023 Nobel Prize in Medicine

The 2023 Nobel Prize in Physiology or Medicine has been jointly awarded to Hungarian-American biochemist Katalin Kariko and American physician-scientist Drew Weissman, for work on messenger RNA (mRNA) technology that paved the way for groundbreaking

Brain Injuries After COVID Vaccination - Vimarsana News

Brain Injuries After COVID Vaccination

There are back door routes to the brain. COVID vaccine developers have traversed a path through those doors. ...

Plant protein gum may chew out SARS-CoV-2 - Vimarsana News

Plant protein gum may chew out SARS-CoV-2

Gum made from a plant protein traps SARS-CoV-2, cutting the viral load in saliva, possibly curbing transmission, according to a study.

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection - Vimarsana News

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, Regeneron, ZMapp and MAb114) have been evaluated in a RCT, the Pamoja Tulinde Maisha (PALM) study. Tw...